These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 33527631)

  • 1. Two cases of refractory erythrodermic psoriasis effectively treated with secukinumab and a review of the literature.
    Liu LC; Jin XH; Sun C; Xia JX
    Dermatol Ther; 2021 Mar; 34(2):e14825. PubMed ID: 33527631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erythrodermic psoriasis in a dialyzed patient successfully treated with Secukinumab.
    Pizzatti L; Mugheddu C; Sanna S; Atzori L; Rongioletti F
    Dermatol Ther; 2020 May; 33(3):e13348. PubMed ID: 32239791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine-induced erythrodermic psoriasis in a child successfully treated with secukinumab: A case report and brief literature review.
    Zhao Z; Zhang X; Wang R; Wang Y; Gong L; Li C
    Dermatol Ther; 2022 Sep; 35(9):e15684. PubMed ID: 35789520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secukinumab and acitretin as a combination therapy for three clinical forms of severe psoriasis in multi-drug refractory patients: A case series of high efficacy and safety profile.
    Polat Ekinci A; Bölük KN; Babuna Kobaner G
    Dermatol Ther; 2021 Jan; 34(1):e14704. PubMed ID: 33368934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
    Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
    Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of erythrodermic psoriasis successfully treated with guselkumab.
    Megna M; Ruggiero A; Camela E; Fabbrocini G; Marasca C
    Dermatol Ther; 2020 Mar; 33(2):e13238. PubMed ID: 31997488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A review of secukinumab in psoriasis treatment.
    Berg SH; Balogh EA; Ghamrawi RI; Feldman SR
    Immunotherapy; 2021 Feb; 13(3):201-216. PubMed ID: 33203276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secukinumab dosing optimization in patients with moderate-to-severe plaque psoriasis: results from the randomized, open-label OPTIMISE study.
    Reich K; Puig L; Szepietowski JC; Paul C; Lacour JP; Tsianakas A; Sieder C; Rissler M; Pournara E; Orsenigo R
    Br J Dermatol; 2020 Feb; 182(2):304-315. PubMed ID: 31102257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Erythrodermic Psoriasis in Children with Secukinumab: A Case Report.
    Lu X; Wang W
    Clin Cosmet Investig Dermatol; 2023; 16():1977-1981. PubMed ID: 37539023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood Monocyte Count Can Predict Early Response to Secukinumab Therapy in Patients With Psoriasis.
    Ziolkowska-Banasik D; Hadas E; Pastuszczak M
    J Drugs Dermatol; 2024 Feb; 23(2):74-77. PubMed ID: 38306130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis.
    Blair HA
    Paediatr Drugs; 2021 Nov; 23(6):601-608. PubMed ID: 34665445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
    Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multicenter study.
    Schwensen JF; Clemmensen A; Sand C; Gniadecki R; Skov L; Zachariae C; Iversen L; Rasmussen M; Thomsen SF
    Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 28906051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.
    Bokor-Billmann T; Schäkel K
    J Dermatolog Treat; 2019 May; 30(3):216-220. PubMed ID: 30051725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variation of body regional responses to Ustekinumab and Secukinumab in psoriasis patients: A real-world retrospective study and literature review.
    Cheng PS; Hou PC; Yang CC; Chu CB
    Dermatol Ther; 2022 Dec; 35(12):e15950. PubMed ID: 36263747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study.
    Chiricozzi A; Balato A; Conrad C; Conti A; Dapavo P; Ferreira P; Gaiani FM; Leite L; Malagoli P; Mendes-Bastos P; Megna M; Messina F; Nidegger A; Odorici G; Panduri S; Piaserico S; Piscitelli L; Prignano F; Ribero S; Valerio J; Torres T
    J Dermatolog Treat; 2020 Aug; 31(5):476-483. PubMed ID: 31557063
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis.
    Egeberg A; Bryld LE; Skov L
    J Am Acad Dermatol; 2019 Jul; 81(1):173-178. PubMed ID: 30914343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study.
    Costanzo A; Russo F; Galluzzo M; Stingeni L; Scuderi R; Zichichi L; Papini M; Di Costanzo L; Conti A; Burlando M; Chiricozzi A; Gaiani FM; Mugheddu C; Musumeci ML; Gisondi P; Piaserico S; Dapavo P; Venturini M; Pagnanelli G; Amerio P; Potenza C; Peris K; Cantoresi F; Trevisini S; Loconsole F; Offidani A; Mercuri SR; Lora V; Prignano F; Bartezaghi M; Oliva G; Aloisi E; Orsenigo R
    Acta Derm Venereol; 2021 Oct; 101(10):adv00576. PubMed ID: 33903916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.
    Ohtsuki M; Morita A; Abe M; Takahashi H; Seko N; Karpov A; Shima T; Papavassilis C; Nakagawa H;
    J Dermatol; 2014 Dec; 41(12):1039-46. PubMed ID: 25354738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
    Rich P; Sigurgeirsson B; Thaci D; Ortonne JP; Paul C; Schopf RE; Morita A; Roseau K; Harfst E; Guettner A; Machacek M; Papavassilis C
    Br J Dermatol; 2013 Feb; 168(2):402-11. PubMed ID: 23362969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.